statistiche ricercatore

Continente	#
NA - Nord America	1.483
EU - Europa	801
AS - Asia	379
SA - Sud America	101
Continente sconosciuto - Info sul continente non disponibili	36
AF - Africa	9
Totale	2.809

Nazione	#
US - Stati Uniti d'America	1.455
RU - Federazione Russa	483
SG - Singapore	145
CN - Cina	116
BR - Brasile	90
IE - Irlanda	85
SE - Svezia	50
IT - Italia	42
PL - Polonia	39
DE - Germania	35
HK - Hong Kong	30
FR - Francia	27
VN - Vietnam	26
GB - Regno Unito	16
IN - India	12
BD - Bangladesh	11
CA - Canada	11
TR - Turchia	8
MX - Messico	7
PH - Filippine	5
BE - Belgio	4
ES - Italia	4
FI - Finlandia	4
IQ - Iraq	4
JP - Giappone	4
MA - Marocco	4
AR - Argentina	3
CZ - Repubblica Ceca	3
PK - Pakistan	3
SA - Arabia Saudita	3
UA - Ucraina	3
UZ - Uzbekistan	3
ZA - Sudafrica	3
CR - Costa Rica	2
LT - Lituania	2
NI - Nicaragua	2
NL - Olanda	2
PE - Perù	2
SV - El Salvador	2
VE - Venezuela	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BY - Bielorussia	1
CL - Cile	1
CO - Colombia	1
EC - Ecuador	1
GP - Guadalupe	1
GR - Grecia	1
GT - Guatemala	1
HN - Honduras	1
ID - Indonesia	1
IR - Iran	1
JM - Giamaica	1
KG - Kirghizistan	1
KZ - Kazakistan	1
NG - Nigeria	1
NP - Nepal	1
OM - Oman	1
PS - Palestinian Territory	1
SN - Senegal	1
SR - Suriname	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	2.774

Nome	#
Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities	325
Effects of cyberknife radiotherapy treatment of pituitary adenomas	300
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study	300
Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing[apos]s disease persistent after pituitary surgery	256
Oral mucositis induced by treatment with soft gel formulation of levothyroxine	236
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience	209
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation	190
Comment to ‘glucocorticoid resistance syndrome caused by a novel nr3c1 point mutation’ by al argan et al.	187
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures	185
Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues	172
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective	164
Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing's disease: an Italian, multicenter study	152
Germline targeted next-generation sequencing in patients with adrenal incidentalomas	133
Totale	2.809

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	62	0	0	0	0	0	1	7	4	1	11	4	34
2022/2023	263	20	33	10	27	22	22	2	23	98	1	5	0
2023/2024	57	5	11	5	2	3	19	0	1	0	5	0	6
2024/2025	282	1	4	8	18	16	5	19	50	63	19	39	40
2025/2026	1.075	75	56	56	65	98	201	109	165	155	50	27	18
2026/2027	870	63	715	34	49	9	0	0	0	0	0	0	0
Totale													2.809